One shot that covers a family of variants, not just one.
As the SARS-CoV-2 virus continues its restless evolution, vaccine researchers face a persistent challenge: building immunity that outlasts the pathogen's next transformation. Preclinical findings from Novavax suggest their monovalent XBB.1.5 formulation may offer a partial answer, generating antibodies capable of neutralizing not just one variant but a family of related sub-variants in both mice and primates. The work, still awaiting peer review, arrives as global health regulators have already moved to endorse XBB.1.5 updates for the coming booster season — a convergence of laboratory evidence and institutional judgment that reflects how science and policy now move in uneasy tandem against a fast-moving virus.
- The virus evolves faster than regulators can authorize new vaccines, creating a perpetual race that a single well-designed formulation might help slow.
- Novavax's monovalent XBB.1.5 vaccine outperformed bivalent combinations in generating cross-neutralizing antibodies against multiple Omicron sub-variants in both mice and rhesus macaques.
- Strong CD4+ T cell responses with a Th1 bias emerged consistently across animals with different vaccination histories, suggesting the booster could work broadly across human populations.
- Regulatory bodies — WHO, EMA, and FDA — had already recommended XBB.1.5 updates before this study appeared, and the preclinical data now lend scientific weight to those decisions.
- The research remains a preprint, unreviewed by independent experts, meaning its promising findings carry the caveat that science's own verification process is still underway.
In laboratories testing whether a redesigned vaccine can stay ahead of a shape-shifting virus, Novavax's monovalent XBB.1.5 formulation has shown an encouraging capacity: generating antibodies that neutralize not only the XBB.1.5 variant it was built around, but also related sub-variants like XBB.1.16, XBB.2.3, and the emerging EG.5.1. The findings, shared on the bioRxiv preprint server, come from studies in mice and rhesus macaques.
Researchers compared the monovalent XBB.1.5 vaccine against bivalent formulations that combined the original spike protein with XBB.1.5. Across multiple immunization strategies — including priming with older vaccines and boosting with the new formulation — the monovalent approach consistently produced stronger neutralizing antibody responses against the broader XBB family. The results held across species, lending confidence that the effect reflects genuine immunological robustness rather than a quirk of mouse biology.
The study also examined cellular immunity, finding strong CD4+ T cell responses with a Th1 bias in primates — the kind of immune activation best suited to fighting viral infections. Crucially, this response appeared regardless of what vaccine the animals had previously received, suggesting the booster could be effective across diverse human vaccination histories.
The regulatory backdrop gives the findings added weight: the WHO, EMA, and FDA had already endorsed XBB.1.5 updates for the 2023-2024 booster season before this research appeared. The study now provides laboratory evidence supporting that judgment. Still, peer review has not yet occurred, and the data remain preliminary until independent scrutiny confirms the methods and conclusions.
In laboratories across the country, researchers have been testing whether Novavax's redesigned COVID-19 vaccine can do what the virus keeps trying to prevent: train the immune system to recognize and neutralize variants that haven't even fully emerged yet. The answer, according to a new study posted to the bioRxiv preprint server, appears to be yes—at least in mice and primates.
The vaccine in question is a monovalent formulation built around the XBB.1.5 spike protein, a variant that circulated widely in early 2023. Researchers wanted to know whether this single-variant approach could generate what's called cross-neutralizing antibodies—immune proteins capable of attacking not just XBB.1.5 itself, but related sub-variants like XBB.1.16, XBB.2.3, and the emerging EG.5.1. The motivation was straightforward: the virus evolves faster than regulatory agencies can authorize new vaccines. If a single formulation could protect against a family of variants rather than just one, it would be a significant advantage.
The study compared several vaccine designs. Researchers immunized mice with either the monovalent XBB.1.5 vaccine or a bivalent version combining the original prototype spike protein with XBB.1.5. They also tested what happened when animals received a primary series of one vaccine followed by a booster of another. The results favored the monovalent approach. Mice given two doses of the XBB.1.5 vaccine alone produced stronger neutralizing antibodies against the full range of XBB sub-variants than mice given the bivalent combination. When researchers looked at booster strategies—priming with an older vaccine and then boosting with XBB.1.5—the monovalent booster generated substantial increases in antibody responses.
The researchers then moved to non-human primates, using rhesus macaques to test whether the findings would hold in a model closer to human biology. Macaques that received a primary series of the older bivalent vaccine and were then boosted with monovalent XBB.1.5 showed comparable neutralizing responses against multiple XBB sub-variants. This consistency across species suggested the vaccine's performance was robust, not an artifact of mouse immunology.
Beyond antibodies, the study examined cellular immunity—the T cell response that provides a second layer of protection. Mice and primates immunized with various primary series and boosted with XBB.1.5 all developed strong CD4+ T cell responses, the kind of helper cells that coordinate broader immune defenses. In primates, these responses showed a Th1 bias, meaning they skewed toward the type of immune activation most effective against viral infections. Notably, this cellular response was consistent regardless of what vaccine the animals had received initially, suggesting that XBB.1.5 boosting could work well even in people with different vaccination histories.
The regulatory context matters here. The World Health Organization, European Medicines Agency, and Food and Drug Administration had already recommended updating COVID-19 vaccines to XBB.1.5 formulations for the 2023-2024 booster campaign, citing waning immunity against circulating Omicron variants. This study provides laboratory evidence supporting that decision, showing that a monovalent approach generates both broader antibody coverage and durable cellular responses. The findings suggest that the single-variant strategy may be more effective than trying to cover multiple variants in one shot.
It is important to note that this research has not yet undergone peer review. The study was posted to bioRxiv, a preprint server where researchers share preliminary findings before formal publication. The data are compelling, but they remain preliminary until independent experts have scrutinized the methods and conclusions. Still, the consistency of results across mouse and primate models, combined with the regulatory agencies' prior endorsement of the XBB.1.5 update, suggests the vaccine is likely to perform as intended when it reaches human arms.
Citas Notables
The monovalent XBB.1.5 vaccine induced cross-neutralizing responses against Omicron XBB sub-variants in mice and non-human primates, with booster studies showing similar neutralization regardless of initial vaccination.— Study conclusions
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter whether the vaccine is monovalent or bivalent? Isn't more coverage always better?
You'd think so, but the data suggest otherwise. When you try to pack two different spike proteins into one dose, each one gets less real estate in the immune response. The monovalent XBB.1.5 vaccine, focused entirely on one target, generated stronger antibodies against a broader range of XBB sub-variants than the two-in-one approach.
So the virus is evolving faster than we can update vaccines. How does this study address that problem?
It doesn't solve it, but it buys time. If a single vaccine formulation can neutralize not just the variant it's designed for but also related ones that are emerging, you don't need a new vaccine every few months. You get what they call cross-neutralization—one shot that covers a family of variants.
The study used mice and primates, not humans. How confident should we be in these results?
That's the right skepticism. Animal models are predictive but not perfect. The fact that results were consistent across two different species—mice and macaques—is reassuring. But until this goes through peer review and eventually human trials, it remains preliminary. The regulatory agencies already recommended XBB.1.5 updates, so they're betting on this working, but the final word comes from real-world use.
What's the difference between the antibody response and the T cell response they measured?
Antibodies are the immune system's first responders—they circulate in the blood and can neutralize virus particles before they infect cells. T cells are more like the immune system's memory and coordination center. They help orchestrate the broader response and provide longer-lasting protection. This vaccine triggered both, which is why the researchers think it will hold up well.
If someone was already vaccinated with an older vaccine, does this XBB.1.5 booster still work?
Yes, and that's one of the more encouraging findings. The primates that had received the older bivalent vaccine still mounted strong responses when boosted with XBB.1.5. It suggests the vaccine works well regardless of your prior vaccination history, which matters for a population with mixed immunity backgrounds.